STING1 and neoplasm: Profound therapeutic effects of drugs targeting this pathway have been demonstrated in multiple preclinical murine tumour models and there are multiple ongoing clinical trials assessing the efficacy of STING agonists as monotherapies or in combination with ICI [13].